We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

COOL-AMI EU Case Series Clinical Study (COOL-AMI EU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02070913
Recruitment Status : Recruiting
First Posted : February 25, 2014
Last Update Posted : May 24, 2017
Information provided by (Responsible Party):
ZOLL Circulation, Inc., USA

September 24, 2013
February 25, 2014
May 24, 2017
September 2013
December 2017   (Final data collection date for primary outcome measure)
  • Time from hospital arrival to Percutaneous Coronary Intervention (PCI). [ Time Frame: 24 hours ]
  • Time from hospital arrival to initiation of cooling. [ Time Frame: 24 hours ]
  • Proportion of subjects achieving target temperature. [ Time Frame: 24 hours ]
Same as current
Complete list of historical versions of study NCT02070913 on ClinicalTrials.gov Archive Site
Proportion of those enrolled that complete the study protocol. [ Time Frame: 24 hours ]
Same as current
Not Provided
Not Provided
COOL-AMI EU Case Series Clinical Study
A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With AMI
A single-center, prospective case series clinical study consecutively enrolling up to 10 patients with expected duration of 12 months or less. The study objectives are to evaluate retention and the feasibility of integrating therapeutic hypothermia using the ZOLL IVTM System.
Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients who present with clinical signs and symptoms of acute myocardial infarction and meet all Inclusion and Exclusion criteria will be considered for case study presentation in this clinical trial without regard to age, gender or ethnicity.
Acute Myocardial Infarction
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2017
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient is 18 years of age.
  • The patient must have symptoms consistent with AMI
  • MI with ST-segment elevation
  • The patient is eligible for PCI.
  • The expected timing of the treatment pathway for the patient will allow for at least 10 minutes of cooling with the IVTM System prior to PCI.
  • The patient or patient legal representative is willing to provide written, informed consent to participate in this clinical study.

Exclusion Criteria:

  • The patient has had a previous myocardial infarction
  • The patient is experiencing cardiogenic shock
  • The patient is experiencing acute pulmonary edema.
  • The patient is presenting with cardiac arrest.
  • The patient is presenting with Killip risk stratification class II through IV.
  • The patient is presenting with Atrial Fibrillation.
  • The patient has a history of a prior large myocardial infarct or an infarct in the same segment that is currently affected.
  • The patient requires an immediate surgical or procedural intervention other than PCI
  • The patient has an aortic dissection.
  • The patient has hepatic failure.
  • The patient has end stage kidney disease.
  • The patient is febrile
  • Known chronic Congestive Heart Failure (CHF).
  • Known previous CABG.
  • Known recent stroke
  • Cardio-pulmonary decompensation that has occurred en route to the hospital
  • Contraindications to hypothermia
  • The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated.
  • The patient has a known history of coagulopathy
  • The patient is known to be pregnant
  • The patient has a known hypersensitivity to antishivering medications.
  • Patient has a known history of severe hepatic or renal impairment.
  • The patient has an Inferior Vena Cava filter in place (IVC).
  • The patient has a life expectancy of less than 1 year
  • The patient has a known, unresolved history of drug use
  • The patient is currently enrolled another investigational drug or device trial
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Renée Kochevar rkochevar@zoll.com
Contact: Tracy Roberts 408 419 2968 troberts@zoll.com
Czechia,   Estonia,   Germany,   Hungary,   Lithuania,   Poland,   Serbia,   United Kingdom
Czech Republic
Not Provided
Plan to Share IPD: Undecided
ZOLL Circulation, Inc., USA
ZOLL Circulation, Inc., USA
Not Provided
Not Provided
ZOLL Circulation, Inc., USA
May 2017